PST 674
Alternative Names: PST-674Latest Information Update: 10 Feb 2023
At a glance
- Originator Pharmasum Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dementia
Most Recent Events
- 31 Jan 2023 Preclinical trials in Dementia in Norway (unspecified route) (Pharmasum therapeutics pipeline, January 2023)